News posts – English language
Initial therapeutic target is allopregnanolone April 11, 2024 Dear Friends: Roberto Cosimo Melcangi, PhD, is taking a page out of Robert Oppenheimer’s playbook. The Head of the Neuroendocrinology Unit in the Department of Pharmacological and Biomolecular Sciences at the University of Milano (UniMi) this week launched an initiative to supercharge post-finasteride syndrome (PFS) research and, […]
New UniMi study enumerates pathologies including depression, anxiety, insomnia, and cognitive dysfunction potentially linked to finasteride-induced genetic dysregulation March 16, 2024 Dear Friends: Turns out, post-finasteride syndrome may indeed be all in your head—namely, your hypothalamus and hippocampus. So demonstrates the latest research from the University of Milano (UniMi), which has identified 186 genes in […]
Japanese disproportionality analysis of finasteride ADRs, meanwhile, shows completed suicides 270% higher than expected Jan. 28, 2024 Dear Friends: Canada is taking no chances vis-á-vis finasteride wreaking havoc on its citizens’ psyches. Pre-prescription edict Last week, drug-regulatory authority (DRA) Health Canada (HC), via its monthly Health Product InfoWatch bulletin, informed its nation’s healthcare professionals that: […]
‘My colleagues are seeing many cases’ of this condition, the UniMi endocrinology professor notes in his first-ever long-form TV interview Jan. 7, 2024 Dear Friends: After a decade of being reduced to mere soundbites on TV news reports, Roberto Cosimo Melcangi is finally getting some quality time in the spotlight. Last month, Italy’s Byoblu TV—having […]
PFS Investigator Roberto Melcangi suspects the post-treatment variety springs from neuroendocrine disorder, rather than genital pathology Aug. 28, 2023 Dear Friends: Finasteride use can, and does, lead to erectile dysfunction that can, and does, last indefinitely in a subset of patients. By this point in the epidemiology of PFS, few self-respecting doctors would argue with […]
Pioneering PFS investigator Michael Irwig also finds that just 13% of respondents believe finasteride could cause depression, while 54% believe the drug is ‘unlikely’ or ‘very unlikely’ to do so Aug. 16, 2023 Dear Friends: Despite the fact that the finasteride product label has included depression and persistent loss of libido as possible side effects […]
Aug. 4, 2023 Dear Friends: Finasteride was first approved by the US Food and Drug Administration in April 1993. But let’s put that aside for a moment. Let’s instead step back just a dozen years. In April 2011, I was driving down the Garden State Parkway, on my way from New York City, where I […]
But generics, unfazed by front-facing disclosure that their products ‘can cause psychiatric and/or sexual disorders,’ stay put May 31, 2023 Dear Friends: French resistance to burying Propecia’s sexual and neuropsychiatric side effects apparently proved too much for the medication’s manufacturer. Last week, drug-regulatory authority ANSM issued a news update (English) noting that Organon & Co. (NYSE: […]
Following new safety review, Health Canada working with finasteride manufacturers to strengthen suicidality warning March 27, 2023 Dear Friends: Although the US Food and Drug Administration rarely mentions PFS, its database of side effects speaks volumes about the condition’s epidemiology. Out of control According to new research based in part on the agency’s Adverse Event […]
‘It is still unclear to what extent the lower systemic drug exposure translates into a lower risk of side effects,’ says Deutsche Apotheker Zeitung. ‘The limited number of patients makes it difficult to draw reliable conclusions.’ March 20, 2023 Dear Friends: Germany’s oldest and most widely read pharmaceutical journal has taken a deep dive into […]